Riluzole Clinical Trial for Spinal Cord Injury in Australia
Sydney and Adelaide will join an international multi-centre clinical trial using the drug Riluzole. The Phase II clinical trial, known as RISCIS will be led by Dr Ralph Stanford across sites in Australia. The Spinal Cord Injury Network funded a feasibility study to conduct the trial in Australia and facilitated regular meetings to bring the sites together. It is believed riluzole may improve neurological recovery, reduce inflammation, and protect damaged neural tissue after injury.
Spinal Cord Injury Network Research Showcase
Highlights from the Spinal Cord Injury Network Research Showcase at the NSW Trade & Investment Centre, MLC Centre, Martin Place, in Sydney on 21 April, 2015.
Sydney is set to join an international multi-centre clinical trial using a neuroprotective drug known as riluzole. Read more
This media release was provided to the Spinal Cord Injury Network by the SpineCare Foundation. Read more
The National Trauma Research Institute (NTRI) in Melbourne has released an overview that highlights three key forums on brain and spinal cord injury, conducted in January to July 2014. Read more
The Network is pleased to announce the winners of the 2014 Travel Grants in Memory of Rosalind Nicholson are: Read more
This story was originally published on the Hunter Medical Research Institute website at www.hmri.com.au/2014/06/exercise-best-medicine-spinal-injury-recovery/ Read more